Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations

Oncologist. 2014 Apr;19(4):430. doi: 10.1634/theoncologist.2013-0346. Epub 2014 Mar 20.

Abstract

This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Carboplatin / therapeutic use
  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / secondary
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • ErbB Receptors / genetics*
  • Female
  • Gefitinib
  • Gemcitabine
  • Humans
  • Kidney / pathology
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / pathology
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / secondary
  • Middle Aged
  • Mutation
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use*
  • Urothelium / pathology

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • Deoxycytidine
  • Carboplatin
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib
  • Gemcitabine